Kadcyla® and Herceptin® are two very different products with different active substances never to be used interchangeably. Kadcyla® is **NOT** a generic version of Herceptin® and has different properties, indications and dose.

TAKE CARE *when dealing with prescription names containing* ***trastuzumab***
ALWAYS CONFIRM THE VIAL LABEL

trastuzumab emtansine solution for infusion[1]

Kadcyla® ▼
trastuzumab emtansine

Kadcyla® 100 mg and 160 mg single-use vials contain powder for concentrate for solution for infusion. After reconstitution:

- The 100 mg vial is designed to deliver 5 ml of 20 mg/ml of trastuzumab emtansine
- The 160 mg vial is designed to deliver 8 ml of 20 mg/ml of trastuzumab emtansine

100 mg vial - WHITE

160 mg vial - PURPLE

Dilute in an infusion bag containing 250 ml of 0.45% or 0.9% sodium chloride solution only.

- When using 0.9% sodium chloride solution a 0.22 µm in-line filter is required
- Incompatible with glucose (5%) solution

For metastatic breast cancer ONLY as a single agent - not approved in early breast cancer.

Recommended dose is 3.6 mg/kg administered as an intravenous infusion every 3 weeks (21-day cycle).

- No loading dose required
- Initial dose should be administered as a 90-minute intravenous infusion
- If prior infusion was well tolerated, subsequent doses may be administered as 30-minute infusions
- Dose may be reduced for toxicity: refer to SPC for full information

NOTE

- **DO NOT** substitute Kadcyla® for Herceptin®
- **DO NOT** substitute Herceptin® for Kadcyla®

trastuzumab solution for injection[2]

Herceptin® SC
trastuzumab
subcutaneous

- Each 5 ml vial of contains 600 mg of trastuzumab
- No reconstitution required

600 mg vial - LIGHT BLUE

- The hypodermic injection needle must be attached to the syringe immediately prior to administration, followed by volume adjustment to 5 ml
- Herceptin® subcutaneous formulation is a ready to use solution which should not be mixed or diluted with any other products

For metastatic and early breast cancer.

- Recommended dose is 600 mg irrespective of patient's body weight
- No loading dose
- Administer subcutaneously over 2-5 minutes every 3 weeks

There is no dose reduction schedule for Herceptin® subcutaneous formulation

▼ This medicinal product is subject to additional monitoring.

This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions. Reporting forms and information can be found at www.medicinesauthority.gov.mt/adrportal . Adverse events should also be reported to Roche Products Ltd. Please contact Roche Drug Safety Centre by emailing welwyn.uk_dsc@roche.com or calling +44 (0)1707 367554.

As Kadcyla® is a biological medicine, healthcare professionals should report adverse reactions by brand name and batch number.

References 1. Kadcyla® SPC. 2. Herceptin® Solution for Injection in Vial SPC. 3. Herceptin® Powder for Concentrate for Solution for Infusion SPC

This educational material is provided by Roche Products Limited and is mandatory as a condition of the Marketing Authorisation in order to further minimise important selected risks

trastuzumab solution for infusion[3]

Herceptin®
trastuzumab

- Each 150 mg Herceptin® vial contains 150 mg powder for concentrate for solution for infusion
- After reconstitution, the Herceptin® solution contains 21 mg/ml of trastuzumab

150 mg vial - RED

Dilute in an infusion bag containing 250 ml of 0.9% sodium chloride solution.

- No filter is required
- Incompatible with glucose-containing solutions

For metastatic and early breast cancer.

Weekly schedule

- Recommended loading dose of 4 mg/kg as a 90-minute intravenous infusion
- If the loading dose is well tolerated, administer subsequent doses as a 30-minute infusion at a dose of 2 mg/kg

Three-weekly schedule

- Administer Herceptin® at an initial loading dose of 8 mg/kg body weight as a 90-minute infusion
- If the loading dose is well tolerated, administer subsequent doses as a 30-minute infusion at a dose of 6 mg/kg

There is no dose reduction schedule for Herceptin® solution for infusion

For comprehensive product information please see the accompanying Summary of Product Characteristics (SPC). Over time, the product information is likely to change. These updates to the product information will be available at http://www.medicines.org.uk/emc.

Kadcyla® trastuzumab emtansine and **Herceptin®** trastuzumab
have similar generic names, but important differences, including dosing and indication.

DO NOT ADMINISTER Kadcyla® ***(trastuzumab emtansine)*** **in combination with or in place of Herceptin® (*trastuzumab*).**

Healthcare professionals should use both the invented name Kadcyla® and the full INN when prescribing, preparing the infusion and administering Kadcyla® to patients.

Roche

RXUKTDM1001134 / April 2015